<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01528046</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-16962</org_study_id>
    <secondary_id>SP003</secondary_id>
    <nct_id>NCT01528046</nct_id>
  </id_info>
  <brief_title>Metformin in Children With Relapsed or Refractory Solid Tumors</brief_title>
  <official_title>A Phase I Trial of Dose Escalation of Metformin in Combination With Vincristine, Irinotecan, and Temozolomide in Children With Relapsed or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pediatric Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      H. Lee Moffitt Cancer Center and Research Institute will be the Sunshine Project
      Coordinator, but will not be recruiting locally.

      The purpose of this study is to evaluate the tolerability and safety of escalating doses of
      metformin on a backbone of vincristine, irinotecan and temozolomide (VIT) in children with
      recurrent and refractory solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metformin is an oral anti-diabetes medication that activates AMP-activated protein kinase
      (AMPK). Recent data from in vitro and in vivo experiments, as well as epidemiologic
      retrospective analyses, suggest that metformin has anti-cancer activity. Vincristine,
      irinotecan, and temozolomide (VIT) is a combination of chemotherapeutic agents that have
      different mechanisms of action as well as disparate side effect profiles. Two recent phase 1
      trials have demonstrated that this regimen is safe and well-tolerated in children with
      relapsed and refractory solid tumors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Average of 3 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To determine the maximum tolerated dose (MTD) of metformin when given in conjunction with VIT in children with refractory and relapsed solid tumors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Antitumor Activity</measure>
    <time_frame>Average of 3 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the antitumor activity of the addition of metformin to VIT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Average of 3 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To describe the pharmacokinetics of metformin in children with relapsed malignancies receiving VIT combination chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Average of 3 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To define the pharmacodynamics of metformin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metformin Concentrations</measure>
    <time_frame>Average of 3 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine tissue and tumor metformin concentrations in patients undergoing resection.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Primary Brain Tumors</condition>
  <arm_group>
    <arm_group_label>Metformin in Combination with VIT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive VIT only for their initial cycle of protocol treatment.
All patients who have no significant bone marrow suppression (hematologic parameters recovered by Day 21, meeting eligibility criteria to proceed to next cycle) will proceed with metformin as per dose escalation with the second and all subsequent cycles.
For patients with bone marrow suppression not recovered by Day 21:
Dose modification as per protocol
Second cycle with VIT only, to validate that dose modification has resolved the bone marrow suppression.
Patients who tolerate dose modification with their second cycle will receive metformin with their subsequent cycles as per dose escalation stratum.
Patients who had dose modification and do not recover by Day 21 to meet eligibility criteria will be removed from study prior to receiving metformin and will be considered unevaluable.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine sulfate</intervention_name>
    <description>Vincristine (VCR) = 1.5 mg/m^2/day (maximum dose 2 mg), days 1 and 8, administered as IV bolus over 1-5 minutes</description>
    <arm_group_label>Metformin in Combination with VIT</arm_group_label>
    <other_name>VCR</other_name>
    <other_name>Oncovin</other_name>
    <other_name>NSC #067574</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan (IRN) = 50 mg/m^2/day, days 1-5, IV over 60 minutes</description>
    <arm_group_label>Metformin in Combination with VIT</arm_group_label>
    <other_name>CPT-11</other_name>
    <other_name>Camptothecin-11</other_name>
    <other_name>Camptosar ®</other_name>
    <other_name>NSC#616348</other_name>
    <other_name>IRN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Temozolomide (TEM) = 100 mg/m^2/day PO Days 1-5</description>
    <arm_group_label>Metformin in Combination with VIT</arm_group_label>
    <other_name>Temodar™</other_name>
    <other_name>NSC #362856</other_name>
    <other_name>TEM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin (MET) = dose as per dose escalation, divided BID, PO continuously Metformin will only be started after the completion of first cycle, in patients who have demonstrated no significant bone marrow suppression with VIT only.</description>
    <arm_group_label>Metformin in Combination with VIT</arm_group_label>
    <other_name>Glucophage ®</other_name>
    <other_name>MET</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: Patients must be &gt; 1 year of age and ≤ 18 years of age at time of initiation of
             protocol therapy.

          -  Diagnosis: Patients have a histologically confirmed relapsed or refractory solid
             tumor or primary central nervous system (CNS) malignancy.

          -  Disease Status: Patients must have radiographically measurable disease.

          -  Therapeutic Options: Patients must have relapsed or refractory cancers for which
             there is no known curative option or other available therapy proven to prolong
             survival with an acceptable quality of life.

          -  Performance Level: Karnofsky ≥ 50% for patients older than 10 years old, and Lansky ≥
             50 for patients ≤ 10 years old.

          -  Prior Therapy: Patients may have received prior therapy including vincristine,
             irinotecan, or temozolomide. Patients may not have previously been treated with
             combination therapy of irinotecan and temozolomide.

          -  Patients must be fully recovered from the acute toxic effects of all prior
             chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

               -  Myelosuppressive chemotherapy: Patients must not have received myelosuppressive
                  chemotherapy within 3 weeks of starting protocol therapy, or a minimum of six
                  weeks must have elapsed since prior nitrosurea chemotherapy.

               -  Hematopoietic growth factor: At least 7 days must have elapsed since the last
                  administration of filgrastim, or 14 days since administration of pegfilgrastim.

               -  Biologic (anti-neoplastic agent): At least 7 must have elapsed since the last
                  administration of any biologic agent.

               -  Radiation therapy (XRT): At least 14 days since the last dose of local
                  palliative radiation therapy. Greater than 6 months must have elapsed since the
                  last day of treatment if given total body irradiation, craniospinal irradiation.

               -  Autologous or Allogenic Stem Cell Transplant: Complete resolution of graft
                  versus host disease and no current need for immunosuppressive medication.
                  Greater than 3 months must have elapsed since engraftment and no longer
                  requiring transfusion of platelets or injection of colony stimulating factors.

          -  Organ Function Requirements

               -  Bone Marrow Function: Peripheral absolute neutrophil count (ANC) ≥ 1000/μL;
                  Platelet count ≥ 100,000/μL (no platelet transfusion within 7 days prior to
                  obtaining laboratory result); Hemoglobin ≥ 8.0 gm/dL

               -  Adequate Renal Function: Creatinine clearance or glomerular filtration rate ≥
                  70ml/min/1.73m^2

               -  Adequate Liver Function: Total bilirubin ≤ 1.5x upper limit of normal (ULN) for
                  age; alanine transaminase (ALT) ≤ 5x ULN; Serum albumin ≥ 2gm/dL

          -  Informed Consent: All patients ≥ 18 years of age must sign a written informed
             consent. For patients &lt; 18 years old, the patients' parents or legal guardians must
             sign a written informed consent, unless the patient is an emancipated minor.
             Childhood Assent, when age appropriate as per institutional guidelines, should be
             signed by the participating patient.

        Exclusion Criteria:

          -  Significant organ dysfunction, not meeting inclusion criteria.

          -  Pregnancy or Breast-Feeding woman will not be entered on this study due to risks of
             fetal and teratogenic adverse events as seen in animal/human studies.

          -  Concomitant Medications:

               -  Growth factor: Growth factors that support platelet or white cell number of
                  function must not have been administered within the past 7 days.

               -  Steroids: Patients with CNS tumors who have not been on a stable or decreasing
                  dose of dexamethasone for the past 7 days.

               -  Investigational Drugs: Patients who are currently receiving another
                  investigational drug.

               -  Anti-cancer Agents: Patients who are currently receiving other anti-cancer
                  agents.

               -  Medication Allergy: Allergy or intolerance to agents on this protocol:
                  vincristine, irinotecan, temozolomide, or metformin; Allergy to cephalosporins.

               -  Infection: Patients who have uncontrolled infection, positive blood cultures
                  within the past 48 hours, or receiving treatment for Clostridium difficile
                  infection.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Gill, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>The Children's Hospital at Montefiore, Pediatric Cancer Foundation, Sunshine Project</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Damon Reed, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathleen Manning</last_name>
    <phone>813-745-7412</phone>
    <email>kathleen.manning@moffitt.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Damon Reed, M.D.</last_name>
    <phone>813-745-2297</phone>
    <email>damon.reed@moffitt.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Rogers</last_name>
      <phone>352-265-0027</phone>
      <email>heatherrogers@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Joanne Lagmay, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tung Wynn, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Slayton, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lamis Eldjerou, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Fort, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Levette Dunbar, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Ingram</last_name>
      <phone>904-697-3985</phone>
      <email>iingram@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Scott Bradfield, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Sandler, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Joyce, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cynthia Gauger, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manisha Bansal, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Pitel, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myriam Zayas</last_name>
      <phone>305-243-7846</phone>
      <email>MZayas2@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>John Goldberg, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina Fernandes, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanna Davis, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonello Podda, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreansky Martin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julio Barredo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ofelia Alvarez, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>All Children's Hospital</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Repp, RN</last_name>
      <phone>727-767-4784</phone>
      <email>Ashley.Repp@allkids.org</email>
    </contact>
    <contact_backup>
      <last_name>Frances Hamblin</last_name>
      <phone>727-767-2423</phone>
      <email>frances.hamblin@allkids.org</email>
    </contact_backup>
    <investigator>
      <last_name>Damon Reed, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irmel Ayala, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregory Hale, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nanette Grana, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stacie Stapleton, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kelly Sawczyn, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Mayer, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jody Kerr, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noam Zeffren</last_name>
      <phone>718-741-2356</phone>
      <email>nzeffren@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Gill, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 10, 2013</lastchanged_date>
  <firstreceived_date>February 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>central nervous system (CNS)</keyword>
  <keyword>malignancy</keyword>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <keyword>pediatric</keyword>
  <keyword>recurrent</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
